News

Filter

Current filters:

RLX030

"Breakthrough" status from FDA for Novartis' serelaxin (RLX030) for acute heart failure

21-06-2013

The US Food and Drug Administration has granted Breakthrough Therapy designation status to RLX030 (serelaxin),…

Cardio-vascularNorth AmericaNovartisPharmaceuticalRegulationRLX030serelaxin

Novartis' serelaxin reduces mortality in AHF patients

25-09-2012

Phase III study results released by Swiss drug major Novartis (NOVN: VX) yesterday show that its investigational…

Cardio-vascularNovartisPharmaceuticalRelaxinResearchRLX030serelaxin

COMPANY SPOTLIGHT

Menarini

Back to top